Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/31803
Full metadata record
DC FieldValueLanguage
dc.contributor.authorZiemssen, T.-
dc.contributor.authorBass, A. D.-
dc.contributor.authorBerkovich, R.-
dc.contributor.authorEichau, S.-
dc.contributor.authorHobart, J.-
dc.contributor.authorHunter, S. F.-
dc.contributor.authorLimmroth, V.-
dc.contributor.authorPelletier, D.-
dc.contributor.authorPozzilli, C.-
dc.contributor.authorSchippling, S.-
dc.contributor.authorSinger, B. A.-
dc.contributor.authorSousa, L.-
dc.contributor.authorTraboulsee, A.-
dc.contributor.authorUittlehaag, B. M. J.-
dc.contributor.authorVAN WIJMEERSCH, Bart-
dc.contributor.authorPoole, E. M.-
dc.contributor.authorChoudhry, Z.-
dc.contributor.authorGeertsen, S.-
dc.contributor.authorDaizadeh, N.-
dc.contributor.authorComi, G.-
dc.date.accessioned2020-08-24T11:32:00Z-
dc.date.available2020-08-24T11:32:00Z-
dc.date.issued2020-
dc.date.submitted2020-08-13T10:00:11Z-
dc.identifier.citationEUROPEAN JOURNAL OF NEUROLOGY, 27 , p. 484 -484-
dc.identifier.urihttp://hdl.handle.net/1942/31803-
dc.description.sponsorshipSTUDY SUPPORT: Sanofi-
dc.language.isoen-
dc.publisherWILEY-
dc.rights2020 European Journal of Neurology, 27 (Suppl. 1 (Suppl. 1), 103–522-
dc.titleAlemtuzumab Outcomes Over 9 Years in RRMS Patients With Highly Active Disease From CARE-MS I and II (TOPAZ)-
dc.typeJournal Contribution-
local.bibliographicCitation.conferencedateMAY 23-26, 2020-
local.bibliographicCitation.conferencename6th Congress of the European-Academy-of-Neurology (EAN)-
local.bibliographicCitation.conferenceplaceELECTR NETWORK-
dc.identifier.epage484-
dc.identifier.spage484-
dc.identifier.volume27-
local.format.pages1-
local.bibliographicCitation.jcatM-
local.publisher.place111 RIVER ST, HOBOKEN 07030-5774, NJ USA-
local.type.refereedRefereed-
local.type.specifiedMeeting Abstract-
dc.identifier.isiWOS:000534616801252-
dc.identifier.urlhttps://onlinelibrary.wiley.com/doi/epdf/10.1111/ene.14307-
local.provider.typewosris-
local.uhasselt.uhpubyes-
local.description.affiliation[Ziemssen, T.] Carl Gustav Carus Univ Hosp, Ctr Clin Neurosci, Dresden, Germany.-
local.description.affiliation[Bass, A. D.] Neurol Ctr San Antonio, San Antonio, TX USA.-
local.description.affiliation[Berkovich, R.] Regina Berkovich MD PhD Inc, West Hollywood, CA USA.-
local.description.affiliation[Eichau, S.] Hosp Univ Virgen Macarena, Seville, Spain.-
local.description.affiliation[Hobart, J.] Plymouth Univ, Peninsula Sch Med, Plymouth, Devon, England.-
local.description.affiliation[Hobart, J.] Plymouth Univ, Peninsula Sch Dent, Plymouth, Devon, England.-
local.description.affiliation[Hunter, S. F.] Adv Neurosci Inst, Franklin, TN USA.-
local.description.affiliation[Limmroth, V.] Klin Neurol & Palliat Med, Cologne, Germany.-
local.description.affiliation[Pelletier, D.] Univ Southern Calif, Keck Sch Med, Los Angeles, CA 90007 USA.-
local.description.affiliation[Pozzilli, C.] Sapienza Univ Rome, Dept Human Neurosci, Rome, Italy.-
local.description.affiliation[Schippling, S.] Univ Hosp Zurich, Zurich, Switzerland.-
local.description.affiliation[Schippling, S.] Univ Zurich, Zurich, Switzerland.-
local.description.affiliation[Singer, B. A.] Missouri Baptist Med Ctr, MS Ctr Innovat Care, St Louis, MO USA.-
local.description.affiliation[Sousa, L.] Ctr Hosp & Univ Coimbra, Coimbra, Portugal.-
local.description.affiliation[Traboulsee, A.] Univ British Columbia, Vancouver, BC, Canada.-
local.description.affiliation[Uittlehaag, B. M. J.] Univ Amsterdam, Med Ctr, Amsterdam, Netherlands.-
local.description.affiliation[Van Wijmeersch, B.] Hasselt Univ, Rehabil & MS Ctr Overpelt, BIOMED, Hasselt, Belgium.-
local.description.affiliation[Poole, E. M.; Choudhry, Z.; Daizadeh, N.] Sanofi, Cambridge, MA USA.-
local.description.affiliation[Geertsen, S.] Sanofi, Copenhagen, Denmark.-
local.description.affiliation[Comi, G.] Univ Vita Salute San Raffaele, Milan, Italy.-
item.fulltextWith Fulltext-
item.contributorZiemssen, T.-
item.contributorBass, A. D.-
item.contributorBerkovich, R.-
item.contributorEichau, S.-
item.contributorHobart, J.-
item.contributorHunter, S. F.-
item.contributorLimmroth, V.-
item.contributorPelletier, D.-
item.contributorPozzilli, C.-
item.contributorSchippling, S.-
item.contributorSinger, B. A.-
item.contributorSousa, L.-
item.contributorTraboulsee, A.-
item.contributorUittlehaag, B. M. J.-
item.contributorVAN WIJMEERSCH, Bart-
item.contributorPoole, E. M.-
item.contributorChoudhry, Z.-
item.contributorGeertsen, S.-
item.contributorDaizadeh, N.-
item.contributorComi, G.-
item.fullcitationZiemssen, T.; Bass, A. D.; Berkovich, R.; Eichau, S.; Hobart, J.; Hunter, S. F.; Limmroth, V.; Pelletier, D.; Pozzilli, C.; Schippling, S.; Singer, B. A.; Sousa, L.; Traboulsee, A.; Uittlehaag, B. M. J.; VAN WIJMEERSCH, Bart; Poole, E. M.; Choudhry, Z.; Geertsen, S.; Daizadeh, N. & Comi, G. (2020) Alemtuzumab Outcomes Over 9 Years in RRMS Patients With Highly Active Disease From CARE-MS I and II (TOPAZ). In: EUROPEAN JOURNAL OF NEUROLOGY, 27 , p. 484 -484.-
item.accessRightsRestricted Access-
Appears in Collections:Research publications
Files in This Item:
File Description SizeFormat 
Ziemssen_T_2020.pdf
  Restricted Access		Published version213.57 kBAdobe PDFView/Open    Request a copy
Show simple item record

Google ScholarTM

Check


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.